View Post

Expert Highlights Benefit of PARP Inhibitors in BRCA+ Breast Cancer and Potentially Beyond

In Clinical Studies News by Barbara Jacoby

By: Ellie Leick From: onclive.com The use of PARP inhibitors has greatly expanded in the treatment of patients with BRCA-mutated breast cancer in recent years, according to Melinda L. Telli, MD, and research efforts are now examining these agents in novel combinations and beyond the BRCA setting. In January 2018, olaparib (Lynparza) joined the treatment arsenal for use as a …